IPSC - Century Therapeutics cutting 25% of staff prioritizing pipeline programs
- Century Therapeutics ( NASDAQ: IPSC ) will lay off 25% of its workforce and prioritize certain programs in its pipeline in a move to extend its cash runway into 2026 .
- None of the cancer immunology-focused biotech's candidates are in the clinic. It is partnered with Bristol-Myers Squibb ( BMY ) on CNTY-104 and CNTY-106 for, respectively, acute myeloid leukemia and multiple myeloma, which will continue as as planned.
- Century ( IPSC ) will focus on lead candidate CNTY-101 for B-cell malignancies, as well as CNTY-102 and CNTY-107 for, respectively, B-cell malignancies and solid tumors.
- CNTY-103 for glioblastoma is being deprioritized.
- Seeking Alpha's Quant Rating sees Century ( IPSC ) as a hold.
For further details see:
Century Therapeutics cutting 25% of staff, prioritizing pipeline programs